11/8/2022 0 Comments Mashhad zip code![]() ![]() Nimjee SM, Rusconi CP, Sullenger BA (2005) Aptamers: an emerging class of therapeutics. Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Stoltenburg R, Reinemann C, Strehlitz B (2005) FluMag-SELEX as an advantageous method for DNA aptamer selection. Gopinath SCB (2007) Methods developed for SELEX. Mayer G, Ahmed M-SL, Dolf A, Endl E, Knolle PA, Famulok M (2010) Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures. Biochimie 87(9):921–930ĭua P, Kim S, Lee D-k (2011) Nucleic acid aptamers targeting cell-surface proteins. Pestourie C, Tavitian B, Duconge F (2005) Aptamers against extracellular targets for in vivo applications. ![]() Biosens Bioelectron 82:162–172Įllington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Robati RY, Arab A, Ramezani M, Langroodi FA, Abnous K, Taghdisi SM (2016) Aptasensors for quantitative detection of kanamycin. Biosens Bioelectron 21(10):1851–1858įeng C, Dai S, Wang L (2014) Optical aptasensors for quantitative detection of small biomolecules: a review. Rasooly A, Jacobson J (2006) Development of biosensors for cancer clinical testing. Shao N, Wickstrom E, Panchapakesan B (2008) Nanotube–antibody biosensor arrays for the detection of circulating breast cancer cells. Herr JK, Smith JE, Medley CD, Shangguan D, Tan W (2006) Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells. Clin Cancer Res 10(15):5094–5100Ĭarter LL, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, Collins M, Honjo T, Freeman GJ, Carreno BM (2002) PD-1: PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. ![]() Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M (2004) B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Sunshine J, Taube JM (2015) Pd-1/Pd-L1 inhibitors. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S (2007) Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Res 66(7):3381–3385Ĭhawla A, Philips AV, Alatrash G, Mittendorf E (2014) Immune checkpoints: a therapeutic target in triple negative breast cancer. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Gettinger S, Herbst RS (2014) B7-H1/PD-1 blockade therapy in non–small cell lung cancer: current status and future direction. Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Hasanzadeh M, Shadjou N (2017) Advanced nanomaterials for use in electrochemical and optical immunoassays of carcinoembryonic antigen. Shan J, Ma Z (2017) A review on amperometric immunoassays for tumor markers based on the use of hybrid materials consisting of conducting polymers and noble metal nanomaterials. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |